Nephrogenic fibrosing dermopathy overview

Nephrogenic fibrosing dermopathy Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Nephrogenic fibrosing dermopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Nephrogenic fibrosing dermopathy overview On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Nephrogenic fibrosing dermopathy overview All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Nephrogenic fibrosing dermopathy overview
CDC on Nephrogenic fibrosing dermopathy overview
Nephrogenic fibrosing dermopathy overview in the news
Blogs on Nephrogenic fibrosing dermopathy overview
Directions to Hospitals Treating Nephrogenic fibrosing dermopathy
Risk calculators and risk factors for Nephrogenic fibrosing dermopathy overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis is a rare and serious syndrome that involves fibrosis of skin, joints, eyes, and internal organs. Its cause is not fully understood, but it seems to be associated with exposure to gadolinium (which is frequently used as a contrast substance for MRIs) in patients with severe kidney failure. It does not have a genetic basis.